These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17649802)

  • 21. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
    Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
    Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colonoscopy is the preferred colorectal cancer screening method in a population-based program.
    Marbet UA; Bauerfeind P; Brunner J; Dorta G; Valloton JJ; Delcò F
    Endoscopy; 2008 Aug; 40(8):650-5. PubMed ID: 18609465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
    Tonus C; Neupert G; Sellinger M
    World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study].
    Naumann M; Schaum B; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Dtsch Med Wochenschr; 2004 Aug; 129(34-35):1806-7. PubMed ID: 15314744
    [No Abstract]   [Full Text] [Related]  

  • 28. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stool test for colorectal cancer screening: what is going on?
    Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG
    Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controversies in colorectal cancer screening.
    Pox CP
    Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
    Schulze G
    Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
    Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P
    Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
    Tonus C; Sellinger M; Koss K; Neupert G
    World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
    Lohsiriwat V; Thavichaigarn P; Awapittaya B
    J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
    Shastri YM; Povse N; Schröder O; Stein J
    Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
    [No Abstract]   [Full Text] [Related]  

  • 38. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
    Haug U; Hundt S; Brenner H
    Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal cancer test use--Maryland, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.